{"id":390861,"date":"2017-11-09T00:00:00","date_gmt":"2017-11-09T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0009-2017-biopharma-ulcerative-colitis-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-04-28T11:26:39","modified_gmt":"2026-04-28T11:26:39","slug":"dlsfim0009-2017-biopharma-ulcerative-colitis-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0009-2017-biopharma-ulcerative-colitis-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Ulcerative Colitis | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC\u00a0oral therapies for the moderate to severe population, together with additional emerging agents with novel\u00a0MOAs and a general increase in the use of biologics to maintain disease control, will help drive market growth. In contrast to these factors, the expected generic entry of leading branded conventional agents (e.g., Shire\u2019s Lialda), continuing generic erosion of other conventional agents, and the additional entries and expanded use of less-expensive biosimilar\u00a0TNF-alpha inhibitors (e.g., Pfizer\u2019s Inflectra, Amgen\u2019s Amjevita) will constrain the\u00a0UC\u00a0market. Indeed, given the increasing competition in the\u00a0UC\u00a0market\u2014for both branded and generic\/biosimilar agents\u2014emerging therapies looking to penetrate this market will need to be clearly differentiated from competitors.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat\u00a0UC?<\/li>\n<li>\u00a0What will be the impact of the anticipated entry of generics for the remaining key branded conventional agents (e.g., Lialda, Valeant\u2019s Apriso)?<\/li>\n<li>How do physicians currently perceive biosimilar agents, and what impact are these agents expected to have on the\u00a0UC\u00a0market?<\/li>\n<li>What do\u00a0KOLs think about key emerging therapies (e.g., Pfizer\u2019s Xeljanz, Roche\/Genentech\u2019s etrolizumab, and Celgene\u2019s ozanimod), and where do they see these agents fitting into the treatment algorithm?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390861","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390861\/revisions"}],"predecessor-version":[{"id":576799,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390861\/revisions\/576799"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}